Exploring the Latest Guidelines and Evidence of IBD Management: An Update in Diagnosis and Treatment.
Inflammatory bowel disease (IBD) is a group of chronic inflammatory diseases of the gastrointestinal tract. Early identification and treatment are important to avoid longterm damage from chronic inflammation. There are multiple available treatments now for moderate to severe IBD, which when used app...
| Publicado en: | Journal of Managed Care Medicine Vol. 25; no. 1; pp. 25 - 30 |
|---|---|
| Autor principal: | |
| Formato: | algorithm tables/charts Journal Article |
| Publicado: |
National Association of Managed Care Physicians, Inc.
2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=158584929&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 158584929 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10941525 9084 jtl: Journal of Managed Care Medicine issn: 10941525 maglogo: N pubinfo: dt: 2022 vid: 25 iid: 1 pid: 54351 pub: National Association of Managed Care Physicians, Inc. place: Glen Allen, Virginia artinfo: ui: 158584929 158584929 158584929 158584929 ppf: 25 ppct: 5 formats: fmt: @attributes: type: P tig: atl: Exploring the Latest Guidelines and Evidence of IBD Management: An Update in Diagnosis and Treatment. aug: au: Farraye, Francis A. affil: Director of the Inflammatory Bowel Disease Center and Professor of Medicine, Mayo Clinic, Jacksonville, FL sug: subj: Inflammatory Bowel Diseases Diagnosis Inflammatory Bowel Diseases Therapy Early Intervention Practice Guidelines Crohn Disease Colitis, Ulcerative Biological Markers C-Reactive Protein Guideline Adherence Janus Kinase Inhibitors Therapeutic Use Antibodies, Monoclonal Therapeutic Use Tumor Necrosis Factor Antagonists and Inhibitors ab: Inflammatory bowel disease (IBD) is a group of chronic inflammatory diseases of the gastrointestinal tract. Early identification and treatment are important to avoid longterm damage from chronic inflammation. There are multiple available treatments now for moderate to severe IBD, which when used appropriately over time, should reduce the rate of complications. pubtype: Academic Journal doctype: algorithm tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|